Foundational guide
GHK-Cu Dosage: Grading a Record That Changes Route Halfway
About 180 papers and three registry records. Two legitimate studies cover a facial procedure and a patch, and the compound is sold for injection. The route gap is the finding.
Grading this compound turns up a failure mode the other entries on this site do not have. The literature is real and reasonably large. The registry contains genuine studies. And neither addresses the way the compound is actually sold, which is as an injectable.
That gap is a route change, and it deserves the same scepticism this site applies to a species conversion.
The three records, read by intervention field
| Record | Design | Intervention | Supports |
|---|---|---|---|
| NCT05932732 | Phase 4, n=27, completed | Three HydraFacial treatments | A cosmetic procedure, not the isolated compound |
| NCT07706361 | n=100, not yet recruiting | LifeWave X39 patch | A biomarker response to the sponsor's own patch |
| Excluded | — | — | Sponsor's filings do not survive verification |
Reading the intervention field rather than the title is what separates these. A study can carry a compound's name and be testing a device, a procedure or a consumer product that contains it.
Route as an unlabelled extrapolation
The standard caution in this field concerns species: a rodent quantity per kilogram cannot be scaled to a person. Route deserves equal weight and rarely gets it.
A copper complex applied to skin and the same complex injected differ in distribution, systemic exposure and what any safety observation applies to. The published record covers the first. A ghk cu dosage figure for injection has therefore crossed a boundary that the source material never crossed, and a table conceals the crossing completely.
Three fields, one minute
On any registry record cited for a compound, read the intervention field, the study type and the lead sponsor before the identifier. Those three settle whether the record supports what it is being used to support.
Applied here they reduce an apparently three-study evidence base to two studies about something else, and one that should not have been counted.
Frequently asked questions
- What evidence tier does injected GHK-Cu reach?
- None that applies. No registered study administers it by injection, so there is no human tier for that route, and the topical work does not transfer across a route change.
- What do the registered studies cover?
- A completed Phase 4 facial skin quality study of 27 participants using HydraFacial treatments, and a not yet recruiting study of a wellness patch's effect on circulating GHK sponsored by the patch manufacturer.
- Why is one registry record excluded here?
- Because its sponsor's registry filings do not survive verification. A registration proves a submission was accepted, not that a study exists as described.
- Is the topical literature sound?
- It is substantial, roughly 180 PubMed records covering skin, wound healing and copper transport, and it is about a molecule delivered to a surface.
- Does a sponsor studying its own product invalidate the study?
- No, but it is a disclosure that belongs beside the result. A patch manufacturer measuring what its own patch does to a biomarker has an interest in the direction of the finding.
Limitations of the evidence
This page grades provenance and prints no administration guidance. GHK-Cu holds no medicinal approval in any market. Its published record is overwhelmingly topical and in vitro, and no registered study administers it by injection, so no quantity for an injected preparation can be sourced from a trial or a label. One record returned by a registry search for this compound is filed by a sponsor whose entries do not survive verification and is excluded from the assessment here. Material sold as a research chemical carries a seller's claim about its labelled mass rather than an assay. Nothing here describes or recommends human use.